This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by del Monte, F. Articles by Hajjar, R. J. Search for Related Content PubMed PubMed Citation Articles by del Monte, F. Articles by Hajjar, R. J.

(Circulation. 1999;100:2308.)
© 1999 American Heart Association, Inc.

Brief Rapid Communication

Restoration of Contractile Function in Isolated Cardiomyocytes From Failing Human Hearts by Gene Transfer of SERCA2a

Federica del Monte, MD, PhD; Sian E. Harding, PhD; Ulrich Schmidt, MD, PhD; Takashi Matsui, MD, PhD; Zhao Bin Kang, MD; G. William Dec, MD; Judith K. Gwathmey, VMD, PhD; Anthony Rosenzweig, MD; Roger J. Hajjar, MD

From the Cardiovascular Research Center (F.d.M., U.S., T.M., Z.B.K., A.R.) and the Heart Failure and Cardiac Transplantation Center (G.W.D., R.J.H.), Massachusetts General Hospital, Harvard Medical School, and Boston University School of Medicine (J.K.G.), Boston, Mass; and Imperial College, London, UK (S.E.H.).

Correspondence to Roger J. Hajjar, MD, Cardiovascular Research Center, Massachusetts General Hospital, 149 13th St, CNY-4, Boston, MA 02129. E-mail hajjar{at}cvrc.mgh.harvard.edu

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—Failing human myocardium is characterized by abnormal relaxation, a deficient sarcoplasmic reticulum (SR) Ca²⁺ uptake, and a negative frequency response, which have all been related to a deficiency in the SR Ca²⁺ ATPase (SERCA2a) pump.

Methods and Results—To test the hypothesis that an increase in SERCA2a could improve contractile function in cardiomyocytes, we overexpressed SERCA2a in human ventricular myocytes from 10 patients with end-stage heart failure and examined intracellular Ca²⁺ handling and contractile function. Overexpression of SERCA2a resulted in an increase in both protein expression and pump activity and induced a faster contraction velocity (26.7±6.7% versus 16.6±2.7% shortening per second, P<0.005) and enhanced relaxation velocity (32.0±10.1% versus 15.1±2.4%, P<0.005). Diastolic Ca²⁺ was decreased in failing cardiomyocytes overexpressing SERCA2a (270±26 versus 347±30 nmol/L, P<0.005), whereas systolic Ca²⁺ was increased (601±38 versus 508±25 nmol/L, P<0.05). In addition, the frequency response was normalized in cardiomyocytes overexpressing SERCA2a.

Conclusions—These results support the premise that gene-based therapies and targeting of specific pathways in human heart failure may offer a new modality for the treatment of this disease.

Key Words: contractility • myocytes • gene therapy • sarcoplasmic reticulum

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Contraction and relaxation in cardiac myocytes are tightly regulated by intrinsic mechanisms that govern the sequential rise and fall of cytosolic Ca²⁺. During depolarization, Ca²⁺ entry through the L-type Ca²⁺ channels triggers the release of Ca²⁺ from the sarcoplasmic reticulum (SR) through ryanodine receptors, resulting in activation of the contractile proteins. In human cardiomyocytes, the removal of Ca²⁺ from the cytoplasm is governed mainly by the SR Ca²⁺ ATPase (SERCA2a) pump and to a lesser extent the Na/Ca exchanger.¹ Cardiomyocytes isolated from failing human hearts are characterized by contractile dysfunction, including prolonged relaxation, reduced systolic force, and elevated diastolic force.^{2 3 4 5} These contractile abnormalities are paralleled by abnormal Ca²⁺ homeostasis, such as reduced SR Ca²⁺ release, elevated diastolic Ca²⁺, and reduced rate of Ca²⁺ removal.⁶ In addition, failing human myocardium is characterized by a frequency-dependent decrease in systolic force and Ca²⁺, as opposed to normal myocardium, in which an increase in pacing rate results in potentiation of contractility and an increase in SR Ca²⁺ release.^{3 6 7 8} In the failing heart, the decrease in SR Ca²⁺ load has been linked to a decrease in SERCA2a function.⁹ However, there has been long-standing controversy as to whether the protein level of SERCA2a is decreased in failing human hearts.^{1 6 9 10 11 12} In addition, because human cardiomyocytes rely on the SERCA2a pump to a lesser degree than do rodents (60% versus 90%), the direct implication of a reduction in SERCA2a activity in human failing hearts for overall contractile function has not been clear. In this study, we overexpressed SERCA2a by adenoviral gene transfer in viable human cardiomyocytes from failing and nonfailing human hearts.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Failing human ventricular myocardial tissue was obtained from 10 explanted hearts (5 ischemic and 5 dilated cardiomyopathy) and nonfailing tissue from 3 donor hearts. Myocytes were isolated from 1 g of endocardial tissue removed from the free wall of the left ventricle by enzymatic digestion as previously described.⁵ The proportions of rod-shaped viable cells at the time of isolation were 28±5% (n=10) for failing and 35±8% (n=3) for nonfailing cardiomyocytes (P>0.1), and at 24 hours after infection, they were 19±6% (n=10) and 24±7% (n=3) (P>0.1). After isolation, the cells were resuspended in F10 medium with 0.164 U/100 mL insulin, 50 U/mL penicillin, and 50 U/mL streptomycin, equilibrated to pH 7.4 and infected with the adenoviruses at a multiplicity of infection (MOI) of 100. Two first-generation type 5 recombinant adenoviruses were used in the study: Ad.GFP, which carries the green fluorescent protein under the control of the cytomegalovirus promoter, and Ad.SERCA2a, which carries both the SERCA2a and GFP genes, each under the control of separate cytomegalovirus promoters. After 24 hours, myocytes were placed in a flow chamber on the stage of an inverted microscope, superfused with oxygenated Krebs-Henseleit solution, and electrically stimulated with biphasic pulse (0.2 Hz, 50% above threshold).⁵ Contraction amplitude and rates of contraction and relaxation were recorded online with a video edge-detection system and data acquisition software (Ion Optix). The fluorescent Ca²⁺ indicator fura 2 (Molecular Probes) was used to measure intracellular Ca²⁺ with a dual-excitation spectrofluorometer (IonOptix) as described previously.¹³ We isolated SR membranes from ventricular myocytes, and SERCA2a activity assays were carried out on the basis of a pyruvate/NADH coupled reaction at [Ca²⁺] of 10 µmol/L as previously described.¹³ SDS-PAGE was performed on the isolated membranes under reducing conditions on a 7.5% separation gel with a 4% stacking gel and immunoblotted with 1:2500 diluted monoclonal anti-SERCA2 antibody (Affinity BioReagents). The blot was then incubated in a chemiluminescence system and exposed to an X-OMAT AR x-ray film (Fuji Films) for 1 minute. Data were presented as mean±SD and were analyzed with a 1-way ANOVA, with statistical differences identified at P<0.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
The coexpression of GFP allowed us to identify the cells that were infected and expressing the transgene (Figure 1a). Figure 1b shows tracings from representative cardiomyocytes isolated from failing hearts, which are characterized by decreased shortening and prolonged relaxation compared with the donor nonfailing cardiomyocytes. Overexpression of SERCA2a in failing cardiomyocytes induced a faster contraction velocity (26.7±6.7% versus 16.6±2.7% shortening per second, P<0.005) and enhanced relaxation velocity (32.0±10.1% versus 15.1±2.4%, P<0.005). Diastolic Ca²⁺ was decreased in failing cardiomyocytes overexpressing SERCA2a (270±26 versus 347±30 nmol/L, P<0.005), whereas systolic Ca²⁺ was increased (601±38 versus 508±25 nmol/L, P<0.05). Because a negative frequency response is a distinctive characteristic of failing myocardium, we tested whether an increase in SERCA2a expression restores the frequency response to normal. As shown in Figure 1c, increasing the frequency of stimulation in nonfailing cardiomyocytes induced an increase in contraction and intracellular Ca²⁺ with little change in diastolic Ca²⁺. In failing cardiomyocytes, increasing the frequency of stimulation induced a decrease in contraction and a large increase in diastolic cell length and diastolic Ca²⁺. Overexpression of SERCA2a in failing cardiomyocytes restored the frequency response, with increasing contraction at increasing frequencies. However, at high stimulation frequencies (2 Hz), both diastolic Ca²⁺ and cell length increased, but to a lesser degree than in failing cardiomyocytes infected with Ad.GFP. To verify that overexpression of SERCA2a in the human cardiomyocytes resulted in enhanced SERCA2a expression and in increased SR pump activity, we also examined immunoblots from infected cardiomyocytes and measured enzymatic activity of the SERCA2a. As shown in Figure 2, infection of cardiomyocytes with Ad.SERCA2a resulted in increased expression of SERCA2a protein and enhanced Ca²⁺ ATPase activity (43.2±3.8 versus 72.6±5.1 nmol · mg^-1 · min^-1, n=6, P<0.01).

View larger version (55K): [in this window] [in a new window]   Figure 1. a, After isolation, failing human cardiomyocytes were infected with Ad.SERCA2a. Twenty-four hours after infection, a cardiomyocyte is visualized with white light and at 510 nm with single excitation peak at 490 nm of blue light. Coexpression of GFP demonstrates visually that SERCA2a is being expressed in cell. b, Recordings from cardiomyocytes isolated from donor nonfailing heart and from failing heart infected with either Ad.GFP or Ad.SERCA2a, stimulated at 1 Hz at 37°C. Failing cell had a characteristic decrease in contraction and prolonged relaxation along with a prolonged Ca2+ transient. Overexpression of SERCA2a in failing cardiomyocyte normalized these parameters. c, Recordings from same cardiomyocytes as in b stimulated at increasing frequencies. Failing cardiomyocyte demonstrated a decrease in contraction amplitude and an increase in diastolic tone and Ca2+. Overexpression of SERCA2a restored frequency-dependent increase in contraction amplitude and mitigated increase in diastolic Ca2+ and length.

View larger version (28K): [in this window] [in a new window]   Figure 2. a, Immunoblots of SERCA2a from crude membranes of failing cardiomyocytes infected for 24 hours with Ad.SERCA2a or Ad.GFP. All representative lanes are from failing hearts. Each pair of immunoreactive densities represents paired immunoblots from 1 preparation of failing cardiomyocytes that were infected with either Ad.GFP or Ad.SERCA2a. b, Paired measurements of ATPase activity performed at [Ca2+] of 10 µmol/L in membrane preparations from failing cardiomyocytes infected for 24 hours with Ad.SERCA2a or Ad.GFP.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Cardiac myocytes from failing human hearts of any etiology show a significant impairment of velocities of contraction and relaxation under low stimulation rate, and an alteration of contraction amplitude occurs at higher frequencies of stimulation than with nonfailing myocytes,^{13 14 15} contributing to the systolic and diastolic dysfunction in failing hearts. Abnormalities of the Ca²⁺ uptake by SERCA2a have been shown both in animal models of heart failure and in humans to account for the described functional abnormalities. Restoring the protein levels and function therefore represents a strategy to revoke the defects. Overexpressing SERCA2a was shown to reverse the contractile abnormalities of failing hearts, as we and others have validated in animal models.^{13 14 15} Transgenic mice overexpressing SERCA2a were characterized by higher myocardial contractility, including increased rates of pressure development for contraction and relaxation.^{16 17} Furthermore, in animal models in vivo, overexpressing SERCA2a improved contractile parameters,¹⁸ indicating that enhancing contractility at the cellular level does translate into improved ventricular performance. However, species-dependent differences need to be evaluated in the interpretation of a model and its translation to pathophysiology in humans. In particular, species-dependent differences are known to exist at the level of the SR in terms of Ca²⁺ removal during relaxation. Therefore, it was not clear whether gene transfer of SERCA2a could be used to restore contractility in human cardiomyocytes isolated from failing hearts. The difficulties in manipulating human myocytes, especially from diseased hearts, have thus far limited studies on the feasibility and efficacy of gene therapy in humans, with a growing experience in animal models. In this study, we were able to overexpress SERCA2a in human cardiac myocytes, and we showed that this translated into a normalization of the major characteristic abnormalities of contraction and calcium handling at the cellular level with an enhanced contraction amplitude and velocities of contraction and relaxation, an increase in peak Ca²⁺, and abbreviation of the calcium transient.

Heart failure continues to be a growing health problem in the United States, especially as the population ages. Up to now, treatment regimens can slow the progress of the disease without clearly reversing it.¹⁹ Gene-based therapies and targeting specific pathways in human heart failure may offer a new modality for the treatment of this disease. Overexpression of SERCA2a increases contractility in the short term, but whether targeted gene transfer has long-term benefits, as opposed to the long list of failed inotropic agents, is not yet known. Further experimental work will be necessary to validate the premise that improving contractile parameters at the cellular level can affect overall ventricular performance and survival in heart failure.

	Acknowledgments

 
This work was supported in part by NIH grants HL-50361 and HL-57623 (Dr Hajjar), HL-54202 and HL-59521 (Dr Rosenzweig), and HL-49574 and HL-60323 (Dr Gwathmey); a Doris Duke Charitable Foundation Clinician Scientist Award and American Federation of Aging Research Grant (Dr Hajjar); and British Heart Foundation Grants 97064 and 98043 (Dr Harding). Dr Rosenzweig is an Established Investigator of the American Heart Association. The authors would like to thank the cardiac surgeons at Massachusetts General Hospital for assistance in tissue acquisition and the National Disease Research Interchange (NDRI) for technical assistance.

Received August 12, 1999; revision received September 21, 1999; accepted October 5, 1999.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Arai M, Matsui H, Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res. 1994;74:555–564.[Free Full Text]
   
2. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, Morgan JP. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 1987;61:70–76.[Abstract/Free Full Text]
   
3. Gwathmey JK, Slawsky MT, Hajjar RJ, Briggs GM, Morgan JP. Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium. J Clin Invest. 1990;85:1599–1613.
   
4. Harding SE, Jones SM, O’Gara P, del Monte F, Vescovo G, Poole-Wilson PA. Isolated ventricular myocytes from failing and non-failing human heart: the relation of age and clinical status of patients to isoproterenol response. J Mol Cell Cardiol. 1992;24:549–564.[Medline] [Order article via Infotrieve]
   
5. del Monte F, O’Gara P, Poole-Wilson PA, Yacoub M, Harding SE. Cell geometry and contractile abnormalities of myocytes from failing human left ventricle. Cardiovasc Res. 1995;30:281–290.[Medline] [Order article via Infotrieve]
   
6. Schmidt U, Hajjar RJ, Helm PA, Kim CS, Doye AA, Gwathmey JK. Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J Mol Cell Cardiol. 1998;30:1929–1937.[Medline] [Order article via Infotrieve]
   
7. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992;85:1743–1750.[Abstract/Free Full Text]
   
8. Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation. 1995;92:2540–2549.[Abstract/Free Full Text]
   
9. Hasenfuss G, Reinecke H, Studer R, Meyer M, Pieske B, Holtz J, Holubarsch C, Posival H, Just H, Drexler H. Relation between myocardial function and expression of sarcoplasmic reticulum Ca²⁺-ATPase in failing and nonfailing human myocardium. Circ Res. 1994;75:434–442.[Abstract/Free Full Text]
   
10. Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 1995;92:778–784.[Abstract/Free Full Text]
    
11. Mercadier JJ, Lompre AM, Duc P, Boheler KR, Fraysse JB, Wisnewsky C, Allen PD, Komajda M, Schwartz K. Altered sarcoplasmic reticulum Ca²⁺-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest. 1990;85:305–309.
    
12. Schwinger RH, Bohm M, Schmidt U, Karczewski P, Bavendiek U, Flesch M, Krause EG, Erdmann E. Unchanged protein levels of SERCA II and phospholamban but reduced Ca²⁺ uptake and Ca²⁺-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation. 1995;92:3220–3228.[Abstract/Free Full Text]
    
13. Hajjar RJ, Kang JX, Gwathmey JK, Rosenzweig A. Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation. 1997;95:423–429.[Abstract/Free Full Text]
    
14. Hajjar RJ, Schmidt U, Kang JX, Matsui T, Rosenzweig A. Adenoviral gene transfer of phospholamban in isolated rat cardiomyocytes: rescue effects by concomitant gene transfer of sarcoplasmic reticulum Ca²⁺ ATPase. Circ Res. 1997;81:145–153.[Abstract/Free Full Text]
    
15. Giordano FJ, He H, McDonough P, Meyer M, Sayen MR, Dillmann WH. Adenovirus-mediated gene transfer reconstitutes depressed sarcoplasmic reticulum Ca²⁺-ATPase levels and shortens prolonged cardiac myocyte Ca²⁺ transients. Circulation. 1997;96:400–403.[Abstract/Free Full Text]
    
16. Baker DL, Hashimoto K, Grupp IL, Ji Y, Reed T, Loukianov E, Grupp G, Bhagwhat A, Hoit B, Walsh R, Marban E, Periasamy M. Targeted overexpression of the sarcoplasmic reticulum Ca²⁺-ATPase increases cardiac contractility in transgenic mouse hearts. Circ Res. 1998;83:1205–1214.[Abstract/Free Full Text]
    
17. He H, Giordano FJ, Hilal-Dandan R, Choi DJ, Rockman HA, McDonough PM, Bluhm WF, Meyer M, Sayen MR, Swanson E, Dillmann WH. Overexpression of the rat sarcoplasmic reticulum Ca²⁺ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest. 1997;100:380–389.[Medline] [Order article via Infotrieve]
    
18. Miyamoto MI, Guerrero JL, Schmidt U, Gwathmey JK, Dec GW, Rosenzweig A, Hajjar RJ. Adenoviral gene transfer of SERCA2a improves LV function in aortic-banded rats in transition to heart failure. Circulation. 1998;98:736. Abstract.
    
19. Stevenson LW. Inotropic therapy for heart failure. N Engl J Med. 1998;339:1848–1850.[Free Full Text]
    

This article has been cited by other articles:

				L. E. Vinge, P. W. Raake, and W. J. Koch Gene Therapy in Heart Failure Circ. Res., June 20, 2008; 102(12): 1458 - 1470. [Abstract] [Full Text] [PDF]

				S. M. Day, P. Coutu, W. Wang, T. Herron, I. Turner, M. Shillingford, N. C. LaCross, K. L. Converso, L. Piao, J. Li, et al. Cardiac-directed parvalbumin transgene expression in mice shows marked heart rate dependence of delayed Ca2+ buffering action Physiol Genomics, May 9, 2008; 33(3): 312 - 322. [Abstract] [Full Text] [PDF]

				Y. Kawase, H. Q. Ly, F. Prunier, D. Lebeche, Y. Shi, H. Jin, L. Hadri, R. Yoneyama, K. Hoshino, Y. Takewa, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1112 - 1119. [Abstract] [Full Text] [PDF]

				R. Beeri, C. Yosefy, J. L. Guerrero, F. Nesta, S. Abedat, M. Chaput, F. del Monte, M. D. Handschumacher, R. Stroud, S. Sullivan, et al. Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 476 - 486. [Abstract] [Full Text] [PDF]

				M. Periasamy, P. Bhupathy, and G. J. Babu Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology Cardiovasc Res, January 15, 2008; 77(2): 265 - 273. [Abstract] [Full Text] [PDF]

				G. Smith Matters of the heart: the physiology of cardiac function and failure Exp Physiol, November 1, 2007; 92(6): 973 - 986. [Abstract] [Full Text] [PDF]

				D. A. Arvanitis, E. Vafiadaki, G.-C. Fan, B. A. Mitton, K. N. Gregory, F. Del Monte, A. Kontrogianni-Konstantopoulos, D. Sanoudou, and E. G. Kranias Histidine-rich Ca-binding protein interacts with sarcoplasmic reticulum Ca-ATPase Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1581 - H1589. [Abstract] [Full Text] [PDF]

				D. W. Rodenbaugh, W. Wang, J. Davis, T. Edwards, J. D. Potter, and J. M. Metzger Parvalbumin isoforms differentially accelerate cardiac myocyte relaxation kinetics in an animal model of diastolic dysfunction Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1705 - H1713. [Abstract] [Full Text] [PDF]

				S. Sakata, D. Lebeche, N. Sakata, Y. Sakata, E. R. Chemaly, L. F. Liang, Y. Takewa, D. Jeong, W. J. Park, Y. Kawase, et al. Targeted gene transfer increases contractility and decreases oxygen cost of contractility in normal rat hearts Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2356 - H2363. [Abstract] [Full Text] [PDF]

				H. Ly, Y. Kawase, R. Yoneyama, and R. J. Hajjar Gene Therapy in the Treatment of Heart Failure Physiology, April 1, 2007; 22(2): 81 - 96. [Abstract] [Full Text] [PDF]

				S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF]

				P. Leszek, J. Korewicki, A. Klisiewicz, J. Janas, A. Biederman, A. Browarek, D. Charlemagne, and P. Trouve Reduced myocardial expression of calcium handling protein in patients with severe chronic mitral regurgitation Eur. J. Cardiothorac. Surg., November 1, 2006; 30(5): 737 - 743. [Abstract] [Full Text] [PDF]

				D. Logeart, L. Vinet, T. Ragot, M. Heimburger, L. Louedec, J.-B. Michel, B. Escoubet, and J.-J. Mercadier Percutaneous intracoronary delivery of SERCA gene increases myocardial function: a tissue Doppler imaging echocardiographic study Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1773 - H1779. [Abstract] [Full Text] [PDF]

				P. M. Heerdt, S. Klotz, and D. Burkhoff Cardiomyopathic Etiology and SERCA2a Reverse Remodeling During Mechanical Support of the Failing Human Heart Anesth. Analg., January 1, 2006; 102(1): 32 - 37. [Abstract] [Full Text] [PDF]

				B M Mayosi, A Kardos, C H Davies, F Gumedze, A Hovnanian, S Burge, and H Watkins Heterozygous disruption of SERCA2a is not associated with impairment of cardiac performance in humans: implications for SERCA2a as a therapeutic target in heart failure Heart, January 1, 2006; 92(1): 105 - 109. [Abstract] [Full Text] [PDF]

				K. R. Sipido and D. Eisner Something old, something new: Changing views on the cellular mechanisms of heart failure Cardiovasc Res, November 1, 2005; 68(2): 167 - 174. [Full Text] [PDF]

				L. Lipskaia, F. del Monte, T. Capiod, S. Yacoubi, L. Hadri, M. Hours, R. J. Hajjar, and A.-M. Lompre Sarco/Endoplasmic Reticulum Ca2+-ATPase Gene Transfer Reduces Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Circ. Res., September 2, 2005; 97(5): 488 - 495. [Abstract] [Full Text] [PDF]

				L. S. Maier, C. Wahl-Schott, W. Horn, S. Weichert, C. Pagel, S. Wagner, N. Dybkova, O. J. Muller, M. Nabauer, W.-M. Franz, et al. Increased SR Ca2+ cycling contributes to improved contractile performance in SERCA2a-overexpressing transgenic rats Cardiovasc Res, September 1, 2005; 67(4): 636 - 646. [Abstract] [Full Text] [PDF]

				B. A. Ahlers, J. Song, J. Wang, X.-Q. Zhang, L. L. Carl, G. M. Tadros, L. I. Rothblum, and J. Y. Cheung Effects of sarcoplasmic reticulum Ca2+-ATPase overexpression in postinfarction rat myocytes J Appl Physiol, June 1, 2005; 98(6): 2169 - 2176. [Abstract] [Full Text] [PDF]

				A. Pathak, F. del Monte, W. Zhao, J.-E. Schultz, J. N. Lorenz, I. Bodi, D. Weiser, H. Hahn, A. N. Carr, F. Syed, et al. Enhancement of Cardiac Function and Suppression of Heart Failure Progression By Inhibition of Protein Phosphatase 1 Circ. Res., April 15, 2005; 96(7): 756 - 766. [Abstract] [Full Text] [PDF]

				P. Coutu and J. M. Metzger Genetic manipulation of calcium-handling proteins in cardiac myocytes. I. Experimental studies Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H601 - H612. [Abstract] [Full Text] [PDF]

				M. A. Stagg and C. M.N. Terracciano Less Na+/H+-exchanger to treat heart failure: a simple solution for a complex problem? Cardiovasc Res, January 1, 2005; 65(1): 10 - 12. [Full Text] [PDF]

				N. Teucher, J. Prestle, T. Seidler, S. Currie, E. B. Elliott, D. F. Reynolds, P. Schott, S. Wagner, H. Kogler, G. Inesi, et al. Excessive Sarcoplasmic/Endoplasmic Reticulum Ca2+-ATPase Expression Causes Increased Sarcoplasmic Reticulum Ca2+ Uptake but Decreases Myocyte Shortening Circulation, December 7, 2004; 110(23): 3553 - 3559. [Abstract] [Full Text] [PDF]

				S. Nishimura, S.-i. Yasuda, M. Katoh, K. P. Yamada, H. Yamashita, Y. Saeki, K. Sunagawa, R. Nagai, T. Hisada, and S. Sugiura Single cell mechanics of rat cardiomyocytes under isometric, unloaded, and physiologically loaded conditions Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H196 - H202. [Abstract] [Full Text] [PDF]

				F. Huq, D. Lebeche, V. Iyer, R. Liao, and R. J. Hajjar Gene Transfer of Parvalbumin Improves Diastolic Dysfunction in Senescent Myocytes Circulation, June 8, 2004; 109(22): 2780 - 2785. [Abstract] [Full Text] [PDF]

				J. C. Hirsch, A. R. Borton, F. P. Albayya, M. W. Russell, R. G. Ohye, and J. M. Metzger Comparative analysis of parvalbumin and SERCA2a cardiac myocyte gene transfer in a large animal model of diastolic dysfunction Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2314 - H2321. [Abstract] [Full Text] [PDF]

				A. M Janczewski, M. Zahid, B. H Lemster, C. S Frye, G. Gibson, Y. Higuchi, E. G Kranias, A. M Feldman, and C. F McTiernan Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model Cardiovasc Res, June 1, 2004; 62(3): 468 - 480. [Abstract] [Full Text] [PDF]

				P. Coutu, C. N. Bennett, E. G. Favre, S. M. Day, and J. M. Metzger Parvalbumin Corrects Slowed Relaxation in Adult Cardiac Myocytes Expressing Hypertrophic Cardiomyopathy-Linked {alpha}-Tropomyosin Mutations Circ. Res., May 14, 2004; 94(9): 1235 - 1241. [Abstract] [Full Text] [PDF]

				Y. Chen, B. Escoubet, F. Prunier, J. Amour, W. S. Simonides, B. Vivien, C. Lenoir, M. Heimburger, C. Choqueux, B. Gellen, et al. Constitutive Cardiac Overexpression of Sarcoplasmic/Endoplasmic Reticulum Ca2+-ATPase Delays Myocardial Failure After Myocardial Infarction in Rats at a Cost of Increased Acute Arrhythmias Circulation, April 20, 2004; 109(15): 1898 - 1903. [Abstract] [Full Text] [PDF]

				F. del Monte, D. Lebeche, J. L. Guerrero, T. Tsuji, A. A. Doye, J. K. Gwathmey, and R. J. Hajjar From the Cover: Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling PNAS, April 13, 2004; 101(15): 5622 - 5627. [Abstract] [Full Text] [PDF]

				M. L. Williams, J. A. Hata, J. Schroder, E. Rampersaud, J. Petrofski, A. Jakoi, C. A. Milano, and W. J. Koch Targeted {beta}-Adrenergic Receptor Kinase ({beta}ARK1) Inhibition by Gene Transfer in Failing Human Hearts Circulation, April 6, 2004; 109(13): 1590 - 1593. [Abstract] [Full Text] [PDF]

				L. G. MELO, A. S. PACHORI, D. KONG, M. GNECCHI, K. WANG, R. E. PRATT, and V. J. DZAU Gene and cell-based therapies for heart disease FASEB J, April 1, 2004; 18(6): 648 - 663. [Abstract] [Full Text] [PDF]

				H. Ma, C. M. Sumbilla, I. K. G. Farrance, M. G. Klein, and G. Inesi Cell-specific expression of SERCA, the exogenous Ca2+ transport ATPase, in cardiac myocytes Am J Physiol Cell Physiol, March 1, 2004; 286(3): C556 - C564. [Abstract] [Full Text]

				G. W. Dorn II and J. D. Molkentin Manipulating Cardiac Contractility in Heart Failure: Data From Mice and Men Circulation, January 20, 2004; 109(2): 150 - 158. [Full Text] [PDF]

				M. J. Lohse, S. Engelhardt, and T. Eschenhagen What Is the Role of {beta}-Adrenergic Signaling in Heart Failure? Circ. Res., November 14, 2003; 93(10): 896 - 906. [Abstract] [Full Text] [PDF]

				C. M.N Terracciano, S. E Harding, D. Adamson, M. Koban, P. Tansley, E. J Birks, P. J.R Barton, and M. H Yacoub Changes in sarcolemmal Ca entry and sarcoplasmic reticulum Ca content in ventricular myocytes from patients with end-stage heart failure following myocardial recovery after combined pharmacological and ventricular assist device therapy Eur. Heart J., July 2, 2003; 24(14): 1329 - 1339. [Abstract] [Full Text] [PDF]

				S. A. Khan, M. W. Skaf, R. W. Harrison, K. Lee, K. M. Minhas, A. Kumar, M. Fradley, A. A. Shoukas, D. E. Berkowitz, and J. M. Hare Nitric Oxide Regulation of Myocardial Contractility and Calcium Cycling: Independent Impact of Neuronal and Endothelial Nitric Oxide Synthases Circ. Res., June 27, 2003; 92(12): 1322 - 1329. [Abstract] [Full Text] [PDF]